Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.Regeneron Pharmaceuticals has received a $450m contract from the US Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense for the manufacture and supply of its antibody cocktail therapy against Covid-19.
Named REGN-COV2, the double antibody cocktail is undergoing two Phase II / III clinical trials to treat Covid-19 patients, as well as a Phase III trial to prevent the disease.
Regeneron already began scaling up manufacturing of the therapy at business risk and this contract should support continued manufacturing.